减重手术与代谢相关脂肪性肝病：2022 年更新。
Bariatric Surgery and Metabolic Dysfunction-Associated Fatty Liver Disease: a 2022 Update.
机构信息
Clarunis, Department of Visceral Surgery, University Centre for Gastrointestinal and Liver Diseases, St. Clara Hospital and University Hospital Basel, Basel, Switzerland.
Chirurgie Zentrum St. Anna, Lucerne, Switzerland.
出版信息
Praxis (Bern 1994). 2023 Feb;112(2):97-102. doi: 10.1024/1661-8157/a003969.
Non-alcoholic fatty liver disease (NAFLD) has been recently termed metabolic dysfunction-associated fatty liver disease (MAFLD) to address the strong association with the metabolic syndrome. The prevalence of MAFLD is significantly increased in obese individuals and treatment of obesity is currently the cornerstone of management of MAFLD. Bariatric and metabolic surgery nowadays emerges as a key therapeutic strategy for the treatment of the MAFLD. This review aims to provide an update on the novel studies reporting the outcomes of bariatric surgery on the spectrum of MAFLD, from hepatic steatosis to cirrhosis.
非酒精性脂肪性肝病（NAFLD）最近被称为代谢功能障碍相关脂肪性肝病（MAFLD），以解决其与代谢综合征的强烈关联。肥胖人群中 MAFLD 的患病率显著增加，而肥胖的治疗目前是 MAFLD 管理的基石。如今，减重和代谢手术已成为治疗 MAFLD 的关键治疗策略。本综述旨在提供最新的研究报告，这些研究报告了减重手术对 MAFLD 谱，从肝脂肪变性到肝硬化的结果。
Zotero 插件